- Danaher Corporation DHR has agreed to acquire privately-held Aldevron for a cash purchase price of approximately $9.6 billion.
- Danaher expects to finance the acquisition using cash on hand or proceeds from the issuance of commercial paper.
- Founded in 1998, Aldevron manufactures plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.
- It employs around 600 people.
- Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.
- Price Action: DHR shares closed at $244.74 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
